AU2007249762A1 - Identification of CDKI pathway inhibitors - Google Patents

Identification of CDKI pathway inhibitors Download PDF

Info

Publication number
AU2007249762A1
AU2007249762A1 AU2007249762A AU2007249762A AU2007249762A1 AU 2007249762 A1 AU2007249762 A1 AU 2007249762A1 AU 2007249762 A AU2007249762 A AU 2007249762A AU 2007249762 A AU2007249762 A AU 2007249762A AU 2007249762 A1 AU2007249762 A1 AU 2007249762A1
Authority
AU
Australia
Prior art keywords
cdki
compound
hydrogen
cell
arrest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007249762A
Other languages
English (en)
Inventor
Bey-Dih Chang
Igor B. Roninson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senex Biotechnology Inc
Original Assignee
Senex Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senex Biotechnology Inc filed Critical Senex Biotechnology Inc
Publication of AU2007249762A1 publication Critical patent/AU2007249762A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2007249762A 2006-05-15 2007-05-15 Identification of CDKI pathway inhibitors Abandoned AU2007249762A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74721306P 2006-05-15 2006-05-15
US60/747,213 2006-05-15
PCT/US2007/011623 WO2007133773A2 (en) 2006-05-15 2007-05-15 Identification of cdki pathway inhibitors

Publications (1)

Publication Number Publication Date
AU2007249762A1 true AU2007249762A1 (en) 2007-11-22

Family

ID=38694544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007249762A Abandoned AU2007249762A1 (en) 2006-05-15 2007-05-15 Identification of CDKI pathway inhibitors

Country Status (6)

Country Link
US (1) US20080033000A1 (enExample)
EP (1) EP2021019A4 (enExample)
JP (1) JP2010505386A (enExample)
AU (1) AU2007249762A1 (enExample)
CA (1) CA2652341A1 (enExample)
WO (1) WO2007133773A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171172A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
KR101696936B1 (ko) * 2008-07-10 2017-01-16 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 퀴놀린카르복사미드 유도체를 유효 성분으로 하는 ｓｔａｔ３ 저해제
US20100190807A1 (en) * 2008-08-26 2010-07-29 Senex Biotechnology, Inc. CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
KR20140048216A (ko) 2011-06-29 2014-04-23 오츠카 세이야쿠 가부시키가이샤 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법
AU2013214783B2 (en) * 2012-02-02 2017-07-06 Senex Biotechnology Inc. CDK8/CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
NZ732511A (en) * 2014-12-15 2018-11-30 Univ Michigan Regents Small molecule inhibitors of egfr and pi3k
WO2018226230A1 (en) * 2017-06-08 2018-12-13 The Children's Medical Center Corporation Compounds and methods for treatment of diamond blackfan anemia
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
AU2020332367A1 (en) * 2019-08-22 2022-02-17 Biohaven Therapeutics Ltd. Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9922173D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
EP1720841B1 (en) * 2004-02-19 2015-11-04 Rexahn Pharmaceuticals, Inc. Quinazoline derivatives and therapeutic use thereof
AU2005238270A1 (en) * 2004-04-28 2005-11-10 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
EP1838879A4 (en) * 2005-01-13 2009-09-23 Senex Biotechnology Inc HIGH-QUALITY SCREENING FOR CLEANING AGAINST CANCER AND AGED DISEASES

Also Published As

Publication number Publication date
CA2652341A1 (en) 2007-11-22
EP2021019A2 (en) 2009-02-11
JP2010505386A (ja) 2010-02-25
US20080033000A1 (en) 2008-02-07
EP2021019A4 (en) 2009-12-09
WO2007133773A3 (en) 2009-01-22
WO2007133773A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
AU2007249762A1 (en) Identification of CDKI pathway inhibitors
US20100190807A1 (en) CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
US20090281129A1 (en) Cdki pathway inhibitors and uses thereof
Roninson Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts
US20200048208A1 (en) TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
Jones et al. Inhibition of nuclear factor κB chemosensitizes non–small cell lung cancer through cytochrome c release and caspase activation
Saunders et al. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma
Mei et al. Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis
Hou et al. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer
Hao et al. MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling
US20080200531A1 (en) CDKI pathway inhibitors as inhibitors of tumor cell growth
Faloon et al. A small molecule inhibitor of the MITF molecular pathway
Bhat et al. Selective repression of YKL-40 by NF-κB in glioma cell lines involves recruitment of histone deacetylase-1 and-2
Venkatesh et al. In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation
Vlčková et al. GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax
Hsieh et al. Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation
Geiger et al. An Inhibitory Function of TRPA1 channels in TGF-β1–driven Fibroblast-to-Myofibroblast Differentiation
JP2009077705A (ja) Ｃｄｋ阻害剤によって調節される遺伝子発現を同定及び調節するための試薬及び方法
Narayan et al. ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells
Yurttas et al. Exploring the molecular mechanism of linagliptin in osteosarcoma cell lines for anti-cancer activity
Greene et al. BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1, 5-benzoxazepines
WO2018213690A1 (en) Compositions and methods for diagnosing and treating diseases and disorders associated with mutant kcnj5
Chen et al. A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma
Zuco et al. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models
JP2017521362A (ja) 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application